NYSE · Financial Statements

Charles River Laboratories International, Inc. (CRL) Revenue, Earnings & Financial Statements

$332.16 NYSE: CRL Market Cap $15.92B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Charles River Laboratories International, Inc. most recently reported annual revenue of $4.0B, a net loss of $144.0M. Revenue grew at an average annual rate of 6.5% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Charles River Laboratories International, Inc.: Revenue rose from $1.7B in 2016 to $4.0B in 2025, a change of +138.8% over 9 years; net profit was positive in 9 of 10 reported years; operating margin moved from 14.1% to 12.7%, a shift of -1.5 percentage points; the most recent year shows a net loss of $144.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$1.7B$1.9B$2.3B$2.6B$2.9B$3.5B$4.0B$4.1B$4.0B$4.0B
Operating Expenses$1.4B$1.6B$1.9B$2.3B$2.5B$3.0B$3.3B$3.5B$3.8B$3.5B
Operating Profit$238.0M$288.0M$331.0M$351.0M$433.0M$590.0M$651.0M$617.0M$227.0M$508.0M
Operating Margin14.1%15.5%14.6%13.4%14.8%16.7%16.4%14.9%5.6%12.7%
Other Income−$15.0M$9.0M−$50.0M−$47.0M$14.0M−$109.0M−$28.0M−$36.0M−$134.0M−$607.0M
Interest$28.0M$30.0M$64.0M$61.0M$86.0M$74.0M$59.0M$137.0M$126.0M$107.0M
Depreciation$127.0M$131.0M$162.0M$198.0M$235.0M$266.0M$304.0M$314.0M$362.0M$403.0M
Profit Before Tax$223.0M$297.0M$282.0M$304.0M$447.0M$481.0M$623.0M$581.0M$93.0M−$100.0M
Tax rate (%)30.0%57.7%19.3%16.4%18.3%17.0%20.9%17.4%72.8%-42.9%
Net Profit$155.0M$123.0M$226.0M$252.0M$364.0M$391.0M$486.0M$475.0M$10.0M−$144.0M
EPS$3.23$2.54$4.62$5.07$7.20$7.60$9.48$9.22$0.20−$2.91

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$1.0B$1.0B$1.0B$1.0B$1.0B$984.0M$1.0B$1.0B$994.0M$996.0M$1.0B$983.0M
Operating Expenses$881.0M$886.0M$874.0M$892.0M$1.2B$909.0M$932.0M$871.0M$874.0M$876.0M$884.0M$780.0M
Operating Profit$133.0M$126.0M$152.0M$117.0M−$168.0M$75.0M$100.0M$134.0M$120.0M$120.0M$120.0M$203.0M
Operating Margin13.1%12.4%14.8%11.6%-16.7%7.6%9.7%13.3%12.1%12.0%11.9%20.6%
Interest$34.0M$35.0M$33.0M$30.0M$28.0M$28.0M$30.0M$25.0M$24.0M$27.0M$30.0M$29.0M
Profit Before Tax$209.0M$99.0M$120.0M$91.0M−$217.0M$36.0M$71.0M$87.0M−$294.0M−$30.0M$53.0M$171.0M
Tax rate (%)9.5%24.8%21.2%23.0%1.4%28.1%26.2%36.3%6.1%50.6%101.4%-96.0%
Net Profit$187.0M$67.0M$90.0M$69.0M−$216.0M$25.0M$52.0M$54.0M−$277.0M−$15.0M−$1.0M$333.0M
EPS$3.62$1.30$1.74$1.33−$4.22$0.50$1.06$1.10−$5.62−$0.30−$0.03$6.86

Over the 10 years reported for Charles River Laboratories International, Inc., borrowings increased from $1.2B in 2016 to $3.1B in 2025, cash stood at $214.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 1.29 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$2.7B$2.9B$3.9B$4.7B$5.5B$7.0B$7.6B$8.2B$7.5B$7.1B
Current Assets$657.0M$827.0M$898.0M$1.0B$1.2B$1.3B$1.4B$1.6B$1.4B$1.4B
Cash$118.0M$164.0M$195.0M$238.0M$228.0M$245.0M$234.0M$277.0M$195.0M$214.0M
Inventory$96.0M$115.0M$128.0M$161.0M$186.0M$199.0M$256.0M$380.0M$279.0M$299.0M
Receivables$364.0M$430.0M$472.0M$514.0M$618.0M$650.0M$752.0M$780.0M$721.0M$709.0M
Fixed Assets$756.0M$782.0M$933.0M$1.2B$1.3B$1.6B$1.9B$2.0B$2.0B$2.0B
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$45.0M$71.0M$89.0M$124.0M$223.0M$201.0M$312.0M$244.0M$218.0M$207.0M
Other Assets$788.0M$805.0M$1.2B$1.5B$1.8B$2.7B$2.9B$3.1B$2.8B$2.8B
Total Liabilities$1.9B$1.9B$2.5B$3.0B$3.3B$4.4B$4.6B$4.5B$4.0B$3.9B
Current Liabilities$430.0M$464.0M$558.0M$710.0M$840.0M$1.0B$1.1B$1.1B$994.0M$1.1B
Borrowings$1.2B$1.1B$1.7B$2.0B$2.2B$3.2B$3.1B$3.1B$2.7B$3.1B
Other Liabilities$623.0M$721.0M$820.0M$1.0B$1.2B$1.2B$1.5B$1.5B$1.3B$859.0M
Equity$1.0M$1.0M$0$0$0$1.0M$1.0M$1.0M$1.0M$0
Reserves$837.0M$1.0B$1.3B$1.6B$2.1B$2.5B$3.0B$3.6B$3.5B$3.2B

For Charles River Laboratories International, Inc., operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $518.0M; free cash flow was positive in 10 of 10 years; financing activities used $416.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$298.0M$316.0M$441.0M$481.0M$547.0M$761.0M$620.0M$684.0M$735.0M$738.0M
Investing Cash Flow−$742.0M−$155.0M−$1.1B−$822.0M−$768.0M−$1.7B−$933.0M−$882.0M−$478.0M−$428.0M
Financing Cash Flow−$21.0M−$73.0M$4.0M−$2.0M$17.0M$3.0M−$62.0M−$10.0M−$139.0M−$416.0M
Net Cash Flow$0$46.0M$31.0M$43.0M−$7.0M$13.0M−$5.0M$43.0M−$79.0M$10.0M
Free Cash Flow$243.0M$234.0M$301.0M$340.0M$380.0M$532.0M$295.0M$365.0M$502.0M$518.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-3.78
EV / EBITDA65.04
FCF Yield2.43%
Quick Ratio1.12
Interest Coverage5.14
Return 1Y104.10%
Return 3Y75.71%
Return 5Y-14.28%

Charles River Laboratories International, Inc. (CRL) financials — frequently asked questions

What is Charles River Laboratories International, Inc.'s annual revenue?

Charles River Laboratories International, Inc. (CRL) reported annual revenue of $4.0B in its most recent fiscal year.

What is Charles River Laboratories International, Inc.'s net profit?

Charles River Laboratories International, Inc. (CRL) reported a net loss of $144.0M in its most recent fiscal year.

What is CRL EV/EBITDA?

Charles River Laboratories International, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 65.04.

Revenue and earnings of other Medical - Diagnostics & Research stocks

TMO revenue $44.6BDHR revenue $24.6BIDXX revenue $4.3BA revenue $6.9BWAT revenue $3.2BIQV revenue $16.3BNTRA revenue $2.3BMTD revenue $4.0BILMN revenue $4.3BLH revenue $14.0BAll Medical - Diagnostics & Research stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens
CRL Overview CRL Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.